I draw the House’s attention to my declaration in the Register of Members’ Financial Interests: until recently, I was an acting consultant addiction psychiatrist. On the point about other uses of nitrous oxide—legitimate medicinal and industrial uses—moving it away from the psychoactive substances regulations to the Misuse of Drugs Act puts a number of limitations on its use in its current settings. What consultation has my right hon. Friend or his Department done with the medical sector as a whole, and also with other commercial providers or users of nitrous oxide, in advance of laying these regulations before the House?
Dangerous Drugs
Proceeding contribution from
Dan Poulter
(Conservative)
in the House of Commons on Tuesday, 12 September 2023.
It occurred during Debates on delegated legislation on Dangerous Drugs.
Type
Proceeding contribution
Reference
737 c849 
Session
2022-23
Chamber / Committee
House of Commons chamber
Librarians' tools
Timestamp
2023-10-05 20:06:11 +0100
URI
http://hansard.intranet.data.parliament.uk/Commons/2023-09-12/23091265000072
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2023-09-12/23091265000072
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2023-09-12/23091265000072